Quarterlytics / Financial Services / Asset Management - Global / AorTech International plc

AorTech International plc

aor · LSE Financial Services
Claim this profile
Ticker aor
Exchange LSE
Sector Financial Services
Industry Asset Management - Global
Employees 1-10
← All annual reports
FY2009 Annual Report · AorTech International plc
Sign in to download
Loading PDF…
AorTech International plc
FY 2009 Annual General Meeting

Expansion, Growth and 
Expansion, Growth and 
Achievement

Marriott Chancery 
Court
London
Sept 2009

License growth and activity

• Major developments

– New and expanded fields:

• License and manufacturing supply agreement for 
• License and manufacturing supply agreement for 

circulatory support pumps

• Royalty bearing Mitral Heart Valve  repair licensee 

approaching human trial phase

• Doubling of pacemaker lead polymer volumes
• First (royalty bearing) vascular stent license –

expected human use 2010

AorTech 2009 Annual Meeting

Progress on many fronts

License growth and activity

• Major developments

– New and expanded fields:

• Market introduction of new royalty bearing non-

vascular stent for prostate treatment
vascular stent for prostate treatment

• 510k submitted for first urology application
• Royalty bearing AV fistula license signed, 

development encouraging

• First header license and component supply 

agreement, several more in evaluation stage
• High value license for use of AorTech polymer 

heart valve in circulatory support pump

AorTech 2009 Annual Meeting

Progress on many fronts

License Maturation

• Expansion of pacemaker lead license to include 

new polymers

• Cardiac device co-development project expanded 

into second application
into second application

• Patient numbers (including all applications) 

approaching 2,000,000
– Zero reported failures

AorTech 2009 Annual Meeting

Progress on many fronts

Component Business

• Expansion of reaction injection molding (RIM) 
evaluations for several Orthopedic applications
• RIM process evolution results in new IP filings 
• High gross margin Bi-Vad component 

manufacturing projected to reach recurring 
manufacturing projected to reach recurring 
revenues in excess of $250k per annum over 
24 months

• High gross margin Polymer HV manufacturing 
for VAD use commenced in September 2009

AorTech 2009 Annual Meeting

Progress on many fronts

Component Business
Elast-Eon RIM Header

AorTech 2009 Annual Meeting

Progress on many fronts

Component Business
Polymer Heart Valve in Cardiac 
Assist Pump

AorTech 2009 Annual Meeting

Progress on many fronts

Summary 

• Revenues of several types and from multiple 

customers and continue to build

• Business operations are sound, consistent and 

highly leveragable

• New polymer materials in pipeline
• Cash position remains strong

AorTech 2009 Annual Meeting

Progress on many fronts